NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Aptevo Therapeutics Inc. APVO
11 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
$-87.27
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-234.6%
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 11-year series below
Revenue
Net income
Per share
USD -87.27
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-234.6%
Return on equity, FY2025
ROE
Operating margin—
Net margin—
Return on assets-121.4%
Each USD of equity lost 235 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−26.6% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−54.2%
−26.6%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.00B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 27.2M
total assets, end of FY2025
Total assetsUSD 27.2M
EquityUSD 17.4M
CashUSD 21.6M
Current ratio3.82×
Equity funds 64% of total assets.
History
11 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
Revenue $B
·
·
·
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.1
−0.1
−0.1
−0.1
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.1
−0.1
−0.1
Income tax $B
0.0
·
·
·
·
·
·
·
−0.0
−0.0
−0.0
Net income $B
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.1
0.0
−0.1
−0.1
EPS, diluted $
−87.27
−31460.23
−2316.83
1.57
−6.07
−5.23
−13.86
−2.39
0.33
−5.55
−2.93
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
ROE %
−234.6
−284.3
−115.3
83.7
−319.6
−124.8
−191.5
−95.5
10.5
−161.5
−66.9
Shares out B
0.00
0.00
0.00
0.01
0.00
0.00
0.00
0.02
0.02
0.02
0.00
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
33 of 33
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed